References in periodicals archive ?
A snapshot of the global therapeutic scenario for Other Central Nervous System Disorders.
Read more inside 'Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010'
Applications of the company's research currently center on hyperparathyroidism, osteoporosis and central nervous system disorders, including chronic pain and brain damage from stroke.
It is used primarily in the diagnosis of central nervous system disorders, including tumor, stroke, multiple sclerosis, epilepsy and spinal disorders.
I believe that the Company's insight into nervous system disorders and strong portfolio of product opportunities present real potential for significant benefits to patients.
Pfizer is the world's largest ethical pharmaceutical company, its main areas in human health being cardiovascular, central nervous system disorders and infectious diseases.
Their combined knowledge and expertise within this market focus will serve ITI well as we seek to develop our lead compound, nasally delivered hydromorphone for the treatment of acute pain, as well as continue to develop our pipeline in the areas of pain and central nervous system disorders.
Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has expanded and further strengthened the intellectual property portfolio for its serotonin platform by entering into an agreement to license certain intellectual property rights from Ipsen (Euronext:IPN), an innovation driven international specialty pharmaceutical group.
Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders.
The conference will feature presentations from more than 290 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology.
Cambria Biosciences is a biopharmaceutical company dedicated to neurodegenerative diseases and other central nervous system disorders.
Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on the timing of its Phase II adjunctive therapy trial with ACP-103 in patients with schizophrenia.